SCHEMBL10033645

SCHEMBL10033645

N=C(Nc1ccccc1)SCCCSC(=N)Nc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
NPSR1 Q6W5P4 1/20 0.50
HDAC3 O15379 1/20 0.45
HDAC4 P56524 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45
HDAC2 Q92769 1/20 0.45
HDAC10 Q969S8 1/20 0.45
HDAC11 Q96DB2 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
HDAC9 Q9UKV0 1/20 0.45
HDAC5 Q9UQL6 1/20 0.45
NOS1 P29475 1/20 0.42
PHGDH O43175 1/20 0.41
GAA P10253 2/20 0.41
TAS2R38 P59533 3/20 0.40
TP53 P04637 2/20 0.40
TSHR P16473 2/20 0.40
HSD17B10 Q99714 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10033639 0.87 NAPRT (0.58) ALDH1A1NPSR1HDAC3HDAC4HDAC1
SCHEMBL10033637 0.86 MAPT (0.47) ALDH1A1NPSR1HDAC3HDAC4HDAC1
Hydrochloric Acid SCHEMBL11846030 0.85 ALDH1A1 (0.40) ALDH1A1NPSR1HDAC3HDAC4HDAC1
SCHEMBL14997857 0.84 MAPT (0.58) ALDH1A1NPSR1HDAC3HDAC4HDAC1
SCHEMBL10033649 0.84 ALDH1A1 (0.46) ALDH1A1NPSR1SMN1; SMN2MEN1KMT2A
SCHEMBL10033646 0.84 RORC (0.50) ALDH1A1NPSR1GAATP53TSHR
SCHEMBL14997856 0.83 PTGS2 (0.48) ALDH1A1NPSR1HDAC3HDAC4HDAC1
SCHEMBL10033641 0.83 CA1 (0.57) ALDH1A1TSHRMEN1KMT2A
SCHEMBL10033644 0.83 ALDH1A1 (0.41) ALDH1A1NPSR1HDAC3HDAC4HDAC1
SCHEMBL10033647 0.82 NPSR1 (0.43) ALDH1A1NPSR1HDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8742156-B2 Anti-viral carbamimidothioic acid esters BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) 2014-06-03 US disclosed
US-8742156-B2 Anti-viral carbamimidothioic acid esters BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) 2014-06-03 US disclosed
US-20130143961-A1 ANTI-VIRAL CARBAMIMIDOTHIOIC ACID ESTERS BRITISH COLUMBIA CANCER AGENCY (CA) 2013-06-06 US disclosed
US-20130143961-A1 ANTI-VIRAL CARBAMIMIDOTHIOIC ACID ESTERS BRITISH COLUMBIA CANCER AGENCY (CA) 2013-06-06 US disclosed
WO-2012021991-A1 ANTI-VIRAL CARBAMIMIDOTHIOIC ACID ESTERS VERSITECH LIMITED (CN) 2012-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130143961-A1 ANTI-VIRAL CARBAMIMIDOTHIOIC ACID ESTERS NAT10, RNGTT, NSUN2 ALDH1A1 1165/4885NPSR1 2283/4885HDAC3 283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.